GlassScriptPhysician profile
Steven Greenstein
NPI 1255627501
$22,510.12
in general payments reported to CMS, 2019-2025
26 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.11 · 2020: $69.61 · 2021: $235 · 2022: $299 · 2023: $1,220 · 2024: $1,442 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,000 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,425 · Honoraria: $2,750 · Travel and Lodging: $1,963 · Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,425.00 |
| Honoraria | $2,750.00 |
| Travel and Lodging | $1,962.78 |
| Food and Beverage | $1,676.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $11,552.49 | 2023-2025 | Epioxa, Travoprost Intraocular Implant - Idose, Kxl System |
| Ziemer USA | $6,425.00 | 2025 | Femtoldv |
| Oculus, INC. | $2,891.24 | 2023-2025 | Pentacam, Na |
| Sun Pharmaceutical Industries INC. | $309.03 | 2020-2025 | Cequa |
| Oyster Point Pharma, INC. | $198.71 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $175.86 | 2024 | |
| Kala Pharmaceuticals, INC. | $150.63 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $121.93 | 2024-2025 | Xdemvy |
| Allergan, INC. | $97.00 | 2019-2022 | |
| Biotissue Holdings INC. | $81.15 | 2022-2025 | |
| Harrow Eye, LLC | $78.16 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $72.05 | 2024-2025 | Miebo, Xiidra |
| Beaver-Visitec International, INC. | $60.75 | 2021 | |
| Dompe US, INC. | $41.90 | 2022-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $34.73 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $32.74 | 2022-2023 | Acthar |
| Ocular Therapeutix, INC. | $29.39 | 2022-2024 | Dextenza |
| Shire North American Group INC | $25.93 | 2019 | |
| Rxsight INC | $24.04 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Abbott Laboratories | $23.89 | 2025 | Cardiomems |
| Sight Sciences, INC. | $20.44 | 2025 | Sion Surgical Instrument, Omni Surgical System |
| Alcon Vision LLC | $17.28 | 2021 | |
| Alimera Sciences, INC. | $16.99 | 2024 | Yutiq, Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.93 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.86 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Greenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.